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Abstract. Background/Aim: Anti-cancer therapies may
deteriorate cognitive functioning, affective functioning and
psychological well-being. Materials and Methods: In this
prospective longitudinal pilot study, premenopausal and
postmenopausal patients received adjuvant endocrine therapy
(ET) (tamoxifen with or without LHRH analog or aromatase
inhibitor) or were observed only (control group). At baseline
testing and 6, 12 and 24 months thereafter, cognitive,
depression and anxiety tests and quality of life (QOL)
measurements were performed. Results: Overall, 46 cases
were evaluated. None of the studied cognitive parameters
differed between the subgroups or changed by time. No
differences were found regarding anxiety, depression or QOL
measures either. Baseline cognitive test and QOL results were
in association with later anxiety and depression. Conclusion:
No cognitive impairment was found during the two years of
ET. Baseline cognitive scores and QOL dimensions proved
good predictors of later anxiety and depression. 
Breast cancer (BC) patients represent the largest group
among long-surviving cancer-affected populations (1).
Adjuvant curative therapies are applied in the majority of
cases that possibly influence their cognitive functioning and
psychological well-being (2-5). The adverse effects of
adjuvant therapies on cognitive functioning including verbal
memory (immediate and delayed recall), visuo-spatial
memory, executive functioning, attention/concentration,
psychomotor speed, verbal fluency, verbal articulation
(language skills) may exert profound effects on quality of
life (QOL) (6-8). Chemotherapy-related cognitive
deterioration originally named as “chemobrain” is a well-
known phenomenon which includes various chemotherapy-
induced deficits and impairments such as decline of verbal
memory and psychomotor functioning (3, 9-11). Similar
consequences of endocrine therapy (ET) have been less
intensively investigated. Some data suggest that these long-
term therapies cause significant cognitive deficits as
compared to surgery-only or healthy control cases (5, 12-14),
while other studies show only minor (15, 16) or no such
effects (17). Since endocrine therapy varies according to age
and risk status, it is even more difficult to distinquish
between the effects of the various treatment regimens
including tamoxifen or the aromatase inhibitors with or
without GnRH analogs (15, 18, 19).
The mechanism of cancer therapy-associated cognitive
changes is complex, including the impact of surgery and
medical therapies and the overwhelming psychological effects
of the diagnosis and therapy (4). Regarding the effects of
chemotherapy, not only neurotoxicity, but also related
endocrine effects may be present. The pure effect of a specific
therapy is difficult to investigate, and needs a large number of
patients. The impact of adjuvant chemotherapy or endocrine
therapy on QOL, depression and anxiety was studied in the
UK START Trial in a large group of 2208 patients at the start
of radiotherapy; only chemotherapy and younger age were
predictors of poorer QOL (8). A systematic review and meta-
analysis of 14 studies demonstrated that ET significantly alters
various cognitive domains both in the short and long terms,
and that tamoxifen impairs cognitive functioning to a lesser
extent than aromatase inhibitors do (5, 15). Estrogen receptors
found in many areas of the brain (hippocampus, prefrontal
cortex and amygdala) are considered important in cognition,
and play a role in performing tasks requiring executive
function, verbal learning, and memory. Estrogen is needed for
tissue integrity. Evidence derived from basic and clinical
research indicates that estradiol stimulates neuroplasticity and
improves cognitive performance (4, 20-22). The blockade of
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estrogen action deprives the brain from modulation via
estradiol resulting in decreased neuroplasticity and impaired
cognitive functioning (21). 
The understanding of previous findings on cognitive
functioning after ET is complicated by the use of different
methods (neuropsychological batteries, definitions of
cognitive impairment or longitudinal decline, the involvement
of BC or healthy controls), the confounding effects of various
cancer treatments, the varying times of menopause, the
patients’ psychological status and treatment compliance and,
many times small sample sizes (4, 5). Limited experience is
gained on old patients (2, 16, 23, 24). Gaining knowledge on
cancer therapy-induced cognitive impairment would yield
practical implications. First, all possible adverse
consequences including cognitive deficits must be carefully
balanced against benefits at treatment decision. Second, if ET
leads to significant cognitive impairment, adherence to
medication may be easily compromised. Third, specific
supportive treatments (training strategies) should be used if
such effects of therapy are identified (25, 26). 
The primary aim of this pilot prospective observational study
was to analyze the effects of ET on cognitive functioning in
premenopausal and postmenopausal BC patients who had not
received chemotherapy as part of their treatment. We also
intended to investigate the depression and anxiety symptoms as
well as the QOL aspects along the assessment time. 
Patients and Methods
All participants provided written informed consent, and none
received financial or material compensation. The present study was
executed in agreement with the Declaration of Helsinki and was
approved by the local Ethics Committee (approval number: SZTE-
REB 15/2009).
Eligible patients were Hungarian premenopausal and
postmenopausal breast cancer patients between the ages of 20-90
years. The only inclusion criterion was curative surgery for estrogen
and/or progesterone receptor positive breast carcinoma. The
exclusion criteria included the need of adjuvant chemotherapy, the
presence of psychiatric/mental disorder, history of stroke,
Parkinson’s disease, alcohol or drug abuse. The administration or
avoidance of adjuvant ET was based on the consideration of the
tumor prognostic factors and patient-related features in accordance
with the institutional and international guidelines. Those patients
who received ET including 20 mg tamoxifen with or without LHRH
analog (leuprolide acetate 3.75 mg or goserelin 3.6 mg every 28
days) or an aromatase inhibitor (letrozole 1 mg or anastrozole 2.5
mg), were compared with patients without any adjuvant ET.
According to the type of ET, two groups were created: 1. tamoxifen-
based group (TAM) including those patients who received
tamoxifen with or without LHRH analog, and 2. the aromatase
inhibitor group (AI). The control group (C) did not receive ET. 
In this prospective longitudinal study, the findings of the first two
years of treatment in the patients who remained adherent to the
assigned protocol were analyzed. The schedule of assessments is
indicated in Figure 1. Briefly, the initial assessment (T1) was
performed after the definitive breast surgery prior to the enrolment
into the study. Follow-up assessments were conducted 6 months
(T2), 12 months (T3) and 24 months (T4) thereafter.
Neuropsychological assessment. All the assessments were
performed by skilled psychologists and psychiatrists under
standardized circumstances, in the morning. The following
neuropsychological tests designed to investigate cognitive capacity,
anxiety, depression and QOL were used. 
Cognitive tests. The Alzheimer’ Disease Assessment Scale (ADAS)
(27, 28) was designed to measure the severity of the most important
cognitive symptoms of Alzheimer’s disease. Its cognitive subscale
(ADAS-Cog) consists of 11 tasks measuring the disturbances of
memory, language, praxis, attention and other cognitive abilities.
Higher total scores indicate more severe cognitive impairments. 
The Cambridge Neuropsychological Testing Automated Battery
(CANTAB) (29) contains touchscreen neuropsychological tests of
cognition, specifically designed to assess central nervous system
disorders and cognitive function across a range of domains. From
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Table I. Patient- and tumor-related characteristics of the study
population. 
Parameter                                  TAM             AI                C         p-Value*
                                                 (n=14)        (n=18)        (n=14)
Mean age, years                        53.6            63.3            56.9          0.01
   SD                                           11.2             5.5              8.6             
   Range                                    31-74          51-71          40-69           
Years of education                    13.3            12.3            14.1          0.41
   SD                                            4.5              3.2              3.6             
   Range                                     5-22            8-18            8-20            
Menostatus                                                                                        0.01
   Premenopausal                    8 (57%)            -            4 (29%)         
   Postmenopausal                  6 (43%)    18 (100%)   10 (71%)        
   Underwent radiotherapy   12 (86 %)   13 (72%)    12 (86%)      0.33
Primary tumor                                                                                     
   pTis                                     2 (14%)           -                  -             0.13
   pT1                                      8 (57%)     11 (61%)    13 (93%)        
   pT2                                      4 (29%)      6 (33%)       1 (7%)          
   pT3                                            -             1 (6%)             -               
Nodal status                                                                                        
   pN0                                      8 (57%)     13 (72%)   14 (100%)     0.08
   pN1                                      5 (36%)      4 (22%)            -               
   pN2                                            -                  -                  -               
   pN3                                       1 (7%)        1 (6%)             -               
Histology                                                                                             
   IDC                                     12 (86%)    11 (61%)    11 (79%)      0.58
   ILC                                            -            4 (22%)       1 (7%)          
   Other                                   2 (14%)      3 (17%)      2 (14%)         
Histological grade                                                                              
                                                      
   0                                           2 (14%)            -                  -               
   1                                           4 (29%)      3 (17%)      7 (50%)         
   2                                           8 (57%)     13 (72%)     4 (29%)       0.13
   3                                                 -            2 (11%)      3 (21%)
SD: Standard deviation. *p-values for analysis of variance.
this battery we chose the Paired Associates Learning (PAL) test
which assesses visual memory and new learning. It has three main
indicators: stages completed (PAL1), stages completed on first trial
(PAL2) and first trial memory score (PAL3).
The Clock-Drawing Test (CDT) (30, 31) is used for screening
cognitive impairment and dementia and a measure of spatial
dysfunction and neglect. The test requires verbal understanding,
memory and spatially coded knowledge in addition to constructive
skills. Maximal total score is 10, lower score indicates cognitive
impairment. 
The Mini-Mental State Examination (MMSE) (32, 33) is the
most commonly used test for basic cognitive skills such as
orientation in time and space, memory, attention and language.
Lower total scores indicate more severe dementia. 
Depression and anxiety tests. The Beck Depression Inventory (BDI)
(34) is one of the most widely used self-administered psychometric
tests for measuring the severity of depression. It contains 21
questions; each answer being scored on a scale value of 0-3. Higher
total scores indicate more severe depressive symptoms. 
The Hamilton Depression Rating Scale (HDRS) (35, 36) is a
multiple-item questionnaire scored and administered by qualified
raters, used to evaluate the severity of depression by probing mood,
feelings of guilt, suicide ideation, insomnia, agitation or retardation,
anxiety, weight loss and somatic symptoms. It contains 17 items
pertaining to symptoms of depression experienced over the past week. 
The Spielberger State-Trait Anxiety Inventory (STAI-S, STAI-T)
(37, 38) is a self-administered anxiety questionnaire. The STAI-S
measures an individual’s emotional response to an actual stressful
situation. The STAI-T measures an individual’s predisposition to
anxiety determined by his/her personality and estimates how a
person generally feels. It consists of 20 items each rated 1-4. A
higher score indicates greater anxiety.
QOL questionnaire. The Functional Assessment of Cancer Therapy–
Breast cancer (FACT-B) (39) was used to measure multidimensional
QOL. It contains 42 statements; patients select their response on a
scale of 0-4. With this questionnaire, 5 dimensions may be assessed:
physical well-being (PWB), social/family well-being (SWB),
emotional well-being (EWB), functional well-being (FWB) and
breast cancer subscale (BCS). 
The tests were administered in the same order to all patients:
BDI, MMSE, ADAS-Cog, CDT, PAL, HDRS, STAI-S, STAI-T and
FACT-B. It took approximately 1 h to complete the tests for every
participant.
Statistical analysis. IBM SPSS Statistics for Windows version 20.0
was used for all analyses. A p<0.05 was considered as statistically
significant.
Changes from T1 to T4 and between groups were analyzed by
using repeated measures of ANOVA in which the cognitive test
(ADAS-Cog, CDT, MMSE, PAL subscales: PAL1, PAL2, PAL3)
scores were within-subject factors, and the treatment type was the
between-subject factor. In this model the follow up time (T1-T4)
was the main factor. We chose this method for its demonstrated
power and capability to compare the three groups and account for
the four assessment times. The same method was used in the cases
of mood questionnaire (BDI, HDRS, STAI- S, STAI-T) scores and
the FACT-B questionnaire (PWS, SWB, EWB, FWB, BCS)
subscales as within-subject factors. 
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Figure 1. Consort diagram of the study.
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Table II. Comparison of cognitive, affective an QOL parameters in the different treatment and control groups during the T1-T4 time intervals.
Parameter                                                            TAM                                   AI                                     C                            F           p-Value*             η2
                                                                          (n=13)                              (n=17)                             (n=15)
                                                                  M                 SD                M                 SD               M                SD                 
                                                                    
Cognitive tests
ADAS-Cog                                                                                                                                                                                                                      
   T1                                                            6                  3.6                 8                   2.6                6                  2.2              1.44            0.207             0.09
   T2                                                            5                  2.4                 7                   3.1                5                  2.1                                                         
   T3                                                            6                  3.4                 6                   2.3                5                  2.5                                                         
   T4                                                            7                  3.8                 6                   2.3                5                  2.4                                                         
CDT                                                                                                                                                                                                                                 
   T1                                                            9                  1.5                 9                   1.8                9                  1.2              0.78            0.549             0.04
   T2                                                            9                  1.8                 9                   1.1              10                  0.4                                                         
   T3                                                            9                  1.9               10                   0.8              10                  0.3                                                         
   T4                                                            9                  2.7                 9                   2.8              10                  0.3                                                         
MMSE                                                                                                                                                                                                                             
   T1                                                          29                  1.2               28                   3.0              29                  0.7              0.37            0.817             0.04
   T2                                                          29                  1.2               29                   1.0              30                  0.7                                                         
   T3                                                          29                  0.8               29                   1.4              29                  1.1                                                         
   T4                                                          29                  1.3               29                   0.8              29                  1.2                                                         
PAL 1                                                                                                                                                                                                                              
   T1                                                            7                  0.7                 6                   0.7                7                  0.6              0.70            0.647             0.04
   T2                                                            7                  1.1                 7                   0.6                7                  0.5                                                         
   T3                                                            7                  0.8                 7                   0.9                7                  0.5                                                         
   T4                                                            7                  0.9                 7                   0.7                7                  0.8                                                         
PAL 2                                                                                                                                                                                                                              
   T1                                                            5                  0.7                 5                   1.3                6                  0.5              1.78            0.108             0.07
   T2                                                            6                  0.9                 6                   1.0                6                  0.9                                                         
   T3                                                            6                  0.7                 5                   1.1                6                  0.7                                                         
   T4                                                            6                  0.6                 5                   0.9                6                  0.7                                                         
PAL 3                                                                                                                                                                                                                              
   T1                                                          15                  3.0               12                   5.1              16                  2.9              1.44            0.226             0.05
   T2                                                          15                  4.3               14                   4.3              17                  2.5                                                         
   T3                                                          20                  9.9               15                   4.5              18                  1.3                                                         
   T4                                                          16                  3.2               14                   3.4              17                  2.9                                                         
Depression and anxiety tests
BDI                                                                                                                                                                                                                                  
   T1                                                            7                  3.6               10                   7.4                7                  6.2              0.71            0.619             0.04
   T2                                                            7                  8.8               10                   8.2                7                  7.4                                                         
   T3                                                            6                  3.9                 8                   7.8                6                  5.5                                                         
   T4                                                            7                  5.9                 7                   7.3                5                  4.4                                                         
HDRS                                                                                                                                                                                                                              
   T1                                                            3                  2.6                 5                   4.8                4                  5.3              0.23            0.965             0.01
   T2                                                            3                  3.8                 5                   5.4                3                  4.7                                                         
   T3                                                            3                  4.1                 6                   6.7                2                  3.2                                                         
   T4                                                            2                  2.6                 5                   6.3                3                  2.4                                                         
STAI-S                                                                                                                                                                                                                            
   T1                                                          40                10.5               44                 16.7              40                  9.7              0.842          0.519             0.04
   T2                                                          41                14.8               39                 13.7              40                12.7                                                         
   T3                                                          36                  9.5               39                 12.9              35                12.3                                                         
   T4                                                          39                11.6               41                 14.6              33                  6.6                                                         
STAI-T                                                                                                                                                                                                                            
   T1                                                          43                  7.4               44                   9.9              44                  9.2              1.70            0.135             0.07
   T2                                                          41                11.5               42                 13.1              42                10.9                                                         
   T3                                                          42                10.7               42                 11.5              37                11.0                                                         
   T4                                                          41                10.7               44                 13.3              38                  8.8                                                         
QOL questionnaire subscales
PWB                                                                                                                                                                                                                                
   T1                                                          25                  3.0               22                   6.4              23                  4.1              0.65            0.694             0.03
   T2                                                          24                  4.1               23                   6.0              23                  4.9                                                         
   T3                                                          25                  3.9               23                   5.0              25                  4.4                                                         
   T4                                                          25                  3.0               22                   6.0              25                  3.7                                   
Table II. Continued
Linear regression analyses with the stepwise method were used
to examine the relationship between the cognitive tests, FACT-B
subscales and anxiety and depression scales. Independent variables
were the cognitive tests (ADAS-Cog, CDT, MMSE, PAL subscales:
PAL1, PAL2, PAL3) and FACT subscales at T1 (PWB, SWB, EWB,
FWB, BCS); dependent variables were the BDI, HDRS and STAI-
S, STAI-T scores at T4.
Results
Descriptive statistics. Although 75 patients were enrolled,
due to the withdrawal of some participants for various
reasons (disease progression, non-compliance to therapy,
withdrawal of consent) at different assessment times, the
analyses were based on the data of 46 patients who attended
to and completed all of the four visits (T1-T4) (Figure 1). 
At the final analysis, the TAM group consisted of 14
participants, the AI group of 18 patients and the C group of
14 participants. The groups showed similar educational level,
but differed by age and menopausal status (p=0.01). Patients
in the control group had obviously lower stage cancers.
Overall, 37 (80%) of the patients received radiotherapy
(Table I).
Neuropsychological performance. All the analyses were
performed with repeated measures of ANOVA with the age
variable as a covariate. This way significant age differences
could be controlled. None of the studied parameters showed
significant changes by time in the overall population or
within the study groups.
First, the mean scores of the cognitive tests were compared
between the study groups. Only slight difference was detected
when all the test data were analyzed (F(36,46)=1.57, p=0.074,
η
2
=0.55). With Bonferroni pairwise comparison, this difference
was not confirmed. When the same values were compared
according to the tests and time points, no differences were
found (Table II). During the two years of observational time,
no difference was detected between the groups regarding the
mean scores of the depression and anxiety tests, taking into
account the time of the test (F(24,62)=1.35, p=0.172, η2=0.34)
(Table II). Likewise, no differences were found in the FACT-
B subscale mean scores during the analysis between the three
groups if the different time points were taken into account
(F(30,52)=0.62, p=0.920, η2=0.26) (Table II).
Next, linear regression models were developed. Various
associations were found between the baseline QOL/cognitive
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Table II. Continued
Parameter                                                            TAM                                   AI                                     C                            F           p-Value*             η2
                                                                          (n=13)                              (n=17)                             (n=15)
                                                                  M                 SD                M                 SD               M                SD                 
   
SWB                                                                                                                                                                                                                                
   T1                                                          22                  4.7               22                   5.6              24                  3.9              0.96            0.444             0.05
   T2                                                          21                  5.1               23                   6.5              24                  3.8                                                         
   T3                                                          22                  5.6               22                   5.3              24                  3.6                                                         
   T4                                                          22                  4.4               22                   6.1              22                  4.5                                                         
EWB                                                                                                                                                                                                                                
   T1                                                          19                  2.8               19                   5.2              20                  4.3              0.41            0.869             0.02
   T2                                                          20                  3.1               19                   5.6              21                  3.9                                                         
   T3                                                          20                  3.5               20                   2.6              22                  3.0                                                         
   T4                                                          20                  2.9               20                   3.7              22                  2.0                                                         
FWB                                                                                                                                                                                                                                
   T1                                                          19                  5.0               19                   4.3              20                  4.8              0.36            0.906             0.02
   T2                                                          19                  5.5               18                   6.9              21                  4.6                                                         
   T3                                                          20                  5.1               17                   6.9              21                  5.0                                                         
   T4                                                          21                  4.7               20                   6.1              21                  4.0                                                         
BCS                                                                                                                                                                                                                                 
   T1                                                          31                  5.2               27                   6.6              32                  7.5              0.85            0.47               0.04
   T2                                                          28                  5.0               27                   7.7              36                23.1                                                         
   T3                                                          32                  6.8               26                   8.7              33                  6.8                                                         
   T4                                                          31                  6.8               27                   9.3              32                  6.8                                                         
                                                                                                                                                                                                                  
M: Mean; SD: standard deviation; η2: partial eta squared – effect size; MMSE: mini-mental state examination; ADAS-Cog: Alzheimer’s disease
assessment scale; CDT: Clock-Drawing test; PAL 1: PAL stages completed; PAL 2: PAL stages completed on first trial; PAL 3: PAL first trial
memory score; HDRS: Hamilton depression rating scale; BDI: beck depression inventory; STAI-S: state-trait anxiety inventory – State subscale;
STAI-T: state-trait anxiety inventory – trait subscale; PWB: physical well-being; SWB: social/family well-being; EWB: emotional well-being; FWB:
functional well-being; BCS: breast cancer subscale.
test results and depression/anxiety scores as measured at the
2-year follow-up visit (T4). The initial cognitive test results
were in association with later depression and anxiety.
Baseline functional and emotional well-being was associated
with later depression and anxiety (Table III). The combined
results of baseline MMSE and FWB predicted BDI scores
two years later (30% (F(2,39)=9.88, p<0.001). Likewise, the
MMSE test and FWB subscale were significant predictors of
STAI-S; the model accounted for 42% of the variance
(F(2,39)=16.05, p<0.001). Also, STAI-T scores at two years
were in association with baseline FWB subscale and MMSE,
the model accounted for 37% of the individual differences
(F(2,39)=12.79, p<0.001). The combined scores of CDT and
EWB were able to predict the HDRS score two years after
enrolment (27% (F(2,38)=8.50, p=0.001). No associations
were detected between the other parameters such as SWB,
BCS, ADAS-Cog and PAL subscales (PAL1, PAL2, PAL3)
and the mood questionnaire scores (Table III).
Discussion
In this pilot prospective study, we detected no negative effect
of 2-year ET on cognitive functioning in the overall patient
population or any of the treatment groups. An unexpected
finding was that baseline cognitive tests and QOL measures
were in association with later depression and anxiety, and their
combined use could even better predict the patient’s long-term
psychological performance status. For future studies, we
propose the use of more specific cognitive batteries for the
consideration of the various cognitive domains, and find
worthy to complement the analysis of different cognitive
domains with that of affective functioning and QOL. 
There are mixed data on the cognitive effects of ET (Table
IV). In the recently published prospective longitudinal Mind
Body Study, Van Dyk et al. (17) reported on the complex
long-term effects of ET on neuropsychological functions
(17). The analysis was based on both neuropsychological
testing and self-reported data in 189 BC patients among
which follow-up was extended to 3-6 years in 102
participants. On the contrary to the perceived hypothesis, no
difference was found in any of the neuropsychological
domains on the basis of ET use. Across most domains, there
was similar improvement in both groups during the years of
follow-up. The significance of these results is justified by the
large number of patients, long follow-up in more than half
of the cases, complex methodology in various domains and
careful statistical analysis; the design of the follow-up
lowered practice effects (17). Nevertheless, the confounder
effects of chemotherapy (about half of the patients in both
groups received chemotherapy <3 months within entering the
study), varying ET and menopausal status were not excluded.
Interestingly, the prior reports on the same study suggested
that ET leads to adverse cognitive outcomes (12). In a recent
metaanalysis, based on a total of 911 BC patients and 911
controls in 14 studies, ET was not associated with any
longitudinal effect on cognitive functions, while in cross-
sectional comparisons, ET patients performed worse on
verbal learning/memory (15). Similarly, no changes in
cognitive functions were found in 2 longitudinal studies (18,
19). Other trials showed that ET affected neuropsychological
functioning overall and verbal learning/memory the most (5,
14, 15). Limited number of studies focus on the comparison
of various endocrine interventions, and their outcome is still
ambiguous due to methodological issues (4, 14, 15, 18, 19).
In a metaanalysis of 14 studies, patients on tamoxifen
therapy performed better than patients on a non-steroidal AI,
but showed less performance differences relative to steroidal
AI-treated patients (15).  Le Rhun et al. (19) investigated the
effects of adjuvant tamoxifen vs. an AI in a randomized
phase III study in 74 postmenopausal BC patients (19). No
differences were found in the verbal episodic memory, visual
memory, psychomotor speed and executive functions or the
patient-reported autonomy, QOL or emotional state measures
(19). In the Co-SOFT study, a homogeneous group of 74
premenopausal BC patients were treated with tamoxifen with
or without ovarian suppression or an AI with ovarian
suppression (18). The primary end-point was objective
cognitive functioning the secondary outcome was patient-
reported outcome between patients with ovarian ablation vs.
patients treated with tamoxifen only. After 1 year of ET, no
significant changes were detected in the global composite
score of the CogState tasks, but patients in the combination
endocrine therapy arms reported greater cognitive decline
than in the tamoxifen-only arm (18).   
Some studies suggest that baseline depression and anxiety
predict later cognitive decline. Tometich et al. (24), in a
longitudinal study, investigated the effects of baseline
anxiety and depression together with fatigue, pain and sleep
disturbances on perceived and objective cognitive functions
in 319 BC patients and 347 non-cancer controls, all aged ≥60
years. Although all groups showed improvements in
neuropsychological scores over time, 16% of the patients
who had high symptoms at baseline had lower perceived and
objective cognition at that time point, and lower perceived
cognition all along the observation time (24). Lower
functional well-being at baseline predicted lower BC-specific
QOL at all time points. In the baseline report of the Mind
Body Study, prior to the start of ET, neuropsychological
performance did not vary based on the use of chemotherapy,
radiotherapy, the avoidance or combined use of these but,
high symptom status correlated with fatigue, pain and sleep
quality (40). Our finding that different indicators of initial
cognitive functioning may be determinants of later decline
in psychological functioning and QOL, has been an original
finding. The initial cognitive test results and emotional well-
being were in association with later depression and anxiety.
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Our results reassure the need of early assessment of
cognitive functioning, mood and QOL in order to implement
intervention if needed (41). If on the basis of initial cognitive
deficit and QOL characteristics risk individuals could be
identified, this would imply special intervention for the
prevention of later depression or anxiety during the follow-
up care of BC survivors (41, 42).
Several methodological biases may compromise the
outcome of studies on the neuropsychological effects of ET.
Although in our study none of the patients received
chemotherapy, still, the type of ET and the age and
menopausal status varied.  The control group consisted of
BC patients with no adjuvant systemic therapy, hence
participants constituted quite homogeneous groups. Some
studies included control groups of healthy individuals (5,
13, 14, 15, 24). BC patients non-treated with ET (5, 12, 14,
15, 17, 40) or both of healthy controls and untreated BC
patients (5, 14, 15). The study of healthy controls may
compensate for physiological timely decline of cognitive
functioning. We, instead, compensated for that by the
statistical methods used. On the other hand, our goal was
to consider the effects of ET in BC patients since this has
been the relevant issue in our everyday practice. Another
issue is study retention, i.e. the proportion and composition
of cases having dropped out (11, 17). Attrition may result
in the selection of data and miss the most vulnerable cases;
this phenomenon is more relevant in studies with long
follow-up. Actually, we experienced a significant drop out
rate of 38.7% due to different reasons. A strength of the
study was the longitudinal design and relatively long
observation time. The limitation of the study, however, was
the small sample size.
The applied neuropsychological tests are not always
appropriate to sensitively detect mild impairments. One of our
aims was to specify appropriate methods for further studies
on BC patients. The CANTAB test simultaneously detecting
a wide range of ability measures is well-established, accurate,
easy to handle, and applicable across age, race and culture.
These features made it an appropriate instrument for the study
of cancer therapy-induced neurotoxicity and cognitive
impairment on the domains of learning and memory,
executive functions and attention (13). To our best
knowledge, the ADAS-Cog test (that we easily had access to)
had not been utilized in breast cancer patients; our experience
does not suggest its usefulness in this patient population. The
MMSE test has been used in breast cancer studies to measure
dementia (43, 44), global cognitive functioning (19), or
chemotherapy- and radiotherapy-related cognitive
deterioration (45, 46). The CDT is a commonly used tool for
detecting cognitive deficiency also in cancer patients (47-50).
The depression and anxiety tests, like BDI (12, 13, 17, 40),
HDRS (51), STAI-S and STAI-T (6, 17, 24, 40) have been
extensively utilized in breast cancer patients. Vardy, Rourke
and Tannock (52) urged for standardization of the methods
used for the investigation of chemotherapy-related cognitive
changes, and recommended a list of brief and comprehensive
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Table III. Associations between the baseline cognitive and QOL characteristics versus depression and anxiety two years after study entry (linear
regression analysis); significant model components are indicated with grey background.
                                     BDI (T4)                                        HDRS (T4)                                     STAI-S (T4)                                      STAI-T (T4)
                      t             β       p-Value   Partial       t            β       p-Value  Partial        t            β       p-Value   Partial         t              β       p-Value   Partial
T1                                                                                                                  Cognitive Tests
MMSE       –2.34     –0.32      0.024     –0.35     –1.0      –0.16     0.322     –0.16     –3.46     –0.43    0.001       –0.48     –2.91      –0.38     0.006     –0.42
ADAS        –0.39     –0.05      0.699     –0.06       0.64      0.09     0.525       0.11     –0.67     –0.08    0.504       –0.11     –0.54      –0.07     0.596     –0.09
CDT           –1.85     –0.23      0.073     –0.29     –2.08    –0.28     0.044     –0.32     –1.83     –0.21    0.074       –0.29     –0.93      –0.12     0.359     –0.15
PAL1            1.25       0.17      0.218       0.2         1.29      0.19     0.205       0.21       0.72       0.09    0.474         0.12       0.88        0.12     0.384       0.14
PAL2            1.54       0.20      0.132       0.24       0.78      0.11      0.442       0.13     –0.77     –0.09    0.449       –0.12       0.26        0.03     0.798       0.04
PAL3            1.45       0.19      0.154       0.23       1.17      0.17     0.250       0.19     –0.17     –0.20    0.868       –0.03       0.23        0.03     0.822       0.04
                                                                                                           QOL questionnaire subscales
PWB          –0.56     –0.08      0.580     –0.09     –1.86    –0.27     0.072     –0.29     –2.00     –0.26    0.053       –0.31     –1.85      –0.25     0.072     –0.29
SWB          –0.10     –0.02      0.919     –0.02     –0.18    –0.03     0.860     –0.03       0.46       0.06    0.647         0.08       0.10        0.01     0.923       0.02
EWB            0.13       0.02      0.899       0.02     –3.76    –0.51     0.001     –0.52     –0.26     –0.05    0.796       –0.04     –0.19      –0.03     0.851     –0.03
FWB          –2.87     –0.39      0.007     –0.42     –1.16    –0.2       0.255     –0.19     –3.2       –0.40    0.003       –0.46     –3.04      –0.40     0.004     –0.44
BCS           –0.06     –0.01      0.950     –0.01       0.002 <0.001   0.998     <0.001   –0.74     –0.09    0.465       –0.12     –0.74      –0.10     0.465     –0.12
MMSE: Mini-mental state examination; ADAS-Cog: Alzheimer’s disease assessment scale; CDT: Clock-Drawing test; PAL 1: PAL stages completed;
PAL 2: PAL stages completed on first trial; PAL 3: PAL first trial memory score; HDRS: Hamilton depression rating scale; BDI: Beck depression
inventory; STAI-S: state-trait anxiety inventory – state subscale; STAI-T: state-trait anxiety inventory – trait subscale; PWB: physical well-being;
SWB: social/family well-being; EWB: emotional well-being; FWB: functional well-being; BCS: breast cancer subscale.
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Table IV. Contemporary studies, reviews or metaanalyses on the neuropsychological effects of systemic therapies in breast cancer patients.
Author                   N,           Control        Systemic                Endpoints                      Methods                            Batteries                         Outcome
                          timing          group            therapy
Ganz 2014          173,          No ET   Previous chemo          Language,                     Objective                             IQ (1)                         ET worsens 
Mind             longitudinal       BC              (N=90)             communication,         neuropsychological           Verbal learning (3)                language 
Body                   6 and                            no previous               cognitive,                        testing                     Verbal memory (4)           communication 
Study              12 months                      chemo (N=83)               neuro-                                                              Visual learning              and diminishes 
                                                               Tam (N=61),          psychological                                                       and memory (12)         neuropsychological 
                                                              AI (n=57) and           functioning                                                     Visuospatial function           improvement
                                                              OFS (N=4) vs.                                                                                              (10, 15)
                                                              no ET (N=51)                                                                                     Psychomotor speed 
                                                                                                                                                                                 (15, 19, 20)                              
                                                                                                                                                                    Executive function (15, 22)
                                                                                                                                                                            Motor speed (16) 
                                                                                                                                  Self-administered                  Depressive  
                                                                                                                                     questionnaire                  symptoms (31) 
                                                                                                                               Self-reported cognitive             Self-reported                            
                                                                                                                                       functioning                  questionnaire for 
                                                                                                                                        complaint              cognitive functions (43)
Bender                397,         Non-BC         Chemo+                 Attention,                      Objective                Verbal intelligence (2)               Poorer
2015              longitudinal                       anastrozole        learning, memory,       neuropsychological             Attention (8, 26)                 execution
                         0, 6, 12,                         (N=114) and      executive functions,                testing                  Learning and memory               function
                       18 months                       Anastrozole        mental flexibiity,                                                        (5, 8, 9, 10)                      during ET
                                                                (N=173) vs.            psychomotor                                                Executive function (8, 23)  
                                                             no ET (N=110)           efficiency,                                                  Mental flexibility (19, 23)
                                                                                           visuospatial ability                                             Psychomotor efficiency 
                                                                                                                                                                                    (16, 21)
                                                                                                                                                                       Visuospatial ability (10)                    
                                                                                                                                  Self-administered      Depressive symptoms (31) 
                                                                                                                                    questionnaires                    Anxiety (34)
                                                                                                                                                                                Fatigue (34)                             
Le Rhun       74 ET, 0, 6,         -           AI (N=37) vs.       Cognitive global                Objective                             IQ (2)                           Negative
2015               12 months                        Tam (N=37)          Verbal episodic        neuropsychological             Global cognitive 
                                                                                                    memory                         testing                      functioning (29) 
                                                                                              Visual episodic                                                      Verbal episodic 
                                                                                                    memory                                                                memory (5) 
                                                                                            Working memory                                                     Visual episodic 
                                                                                          Psychomotor speed                                                     memory (14) 
                                                                                          Executive functions                                           Working memory (4, 13)
                                                                                                                                                                     Processing speed (19, 20)
                                                                                                                                                                           Executive function 
                                                                                                                                                                              (19, 20, 24, 25) 
                                                                                                                                     Self-reported                     Self-reported 
                                                                                                                                         cognitive                     questionnaire for
                                                                                                                              functioning complaint     cognitive functions (44)
Phillips                74,                -               Previous                Cognitive,                     Objective                    Global cognitive           OFS deteriorated 
2016             longitudinal                    chemo (N=21)         Psychological          neuropsychological             functioning (30)             verbal learning
Co-SOFT       12 months,                  Tam+OFS (N=28)          distress,                         testing                                                                   memory as 
                      randomized                      and AI+OFS                fatigue,                Self-administered      Psychological distress (36)          compared
                           study                             (N=26) vs.               insomnia,                 questionnaires                     Fatigue (37)                   to Tam alone
                                                                Tam (N=25)                  QOL                                                                    QOL (47)
                                                                                                                                     Self-reported                    Self-reported
                                                                                                                               cognitive functioning          questionnaire for 
                                                                                                                                        complaint              cognitive functions (45)                    
Van Dyk             189,               -               previous         Learning, memory,              Objective                             IQ (1)                       No difference
2018            cross-sectional                  chemo (N=24)             attention,             neuropsychological          Learning (3, 4, 12)        between groups, but
Mind                                                       ET (N=126)            visuospatial,                     testing                   Memory (3, 4, 10, 12)      fatigue, pain, sleep 
Body                                                      no ET (N=63)     executive function,                                              Attention (15, 19, 27)         correlates with 
Study                                                                                    processing speed                                              Visuospatial functioning           cognitive 
                                                                                           fatigue, pain, sleep                                                          (10, 15)                        functioning
                                                                                                                                                                           Executive function 
                                                                                                                                                                                 (19, 20, 24)
Table IV. Continued
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Table IV. Continued
Author                   N,           Control        Systemic                Endpoints                      Methods                            Batteries                         Outcome
                          timing          group            therapy
                                                                                                                                  Self-administered              Processing speed 
                                                                                                                                    questionnaires                        (16, 20)
                                                                                                                                                                            Sleep quality (39)
                                                                                                                                                                                Fatigue (38)
                                                                                                                                                                    BC Symptom checklist (41)
                                                                                                                                                                     Depressive symptoms (31)
                                                                                                                                                                                Anxiety (35) 
Gregoro-              715,                         chemo (N=109)           Cognitive,              Self-administered    Depression and anxiety (34)    Chemo worsens 
witsch            longitudinal,                    and chemo+ET             anxiety,                   questionnaires       QOL cognitive function (40)      self-reported 
2019                  0, 3, 6,                          (N=252) vs.             depression,          Self-reported cognitive              Self-reported                     cognitive
UMBRELLA     12, 18,                      no chemo, no ET             QOL,               functioning complaint              questionnaire              functioning with
                       24 months                       (N=218) and                                                                                           for cognitive                the most effect 
                                                              no chemo, ET                                                                                         functions (48)                 in pts<55 yrs
                                                                yes (N=135)                      
Van Dyk             189,          No ET          previous         Learning, memory,              Objective                             IQ (1)                           Negative
2019             longitudinal       BC        chemo (N=24)             attention,             neuropsychological           Learning (3, 4, 12) 
Mind                0, 6, 12                         ET (N=126)            visuospatial,                     testing                   Memory (3, 4, 10, 12)
Body                 months,                        no ET (N=63)             execution                                                      Attention (15, 19, 27)
Study                 3-6 yrs                                                           functioning,                                                           Visuospatial 
                                                                                            processing speed                                                 functioning (10, 15)
                                                                                                                                                                        Executive functioning 
                                                                                                                                                                                 (19, 20, 24)
                                                                                                                                  Self-administered       Processing speed (16, 20)
                                                                                                                                    questionnaires                    Anxiety (35)
                                                                                                                                                                             Depression (31)
Tometich        319 BC +        Non-          ET (N=90)       Depression, anxiety,             Objective                 Attention, processing     Psychoneurological 
2019              347 control     cancer        chemo±ET            fatigue, sleep          neuropsychological          speed and executive        symptoms predict
                       (≥60 yrs),         pts             (N=217)                disturbancy,                      testing                 function (11, 15, 19, 28)      lower cognitive 
                      longitudinal                                                    cognition, pain                                            Learning and memory (4, 11)     functioning at 
                    12, 24 months                                                                                       Self-administered                    QOL (49)                     baseline and 
                                                                                                                                    questionnaires         Depressive symptoms (33)           later on
                                                                                                                                                                                Anxiety (35)
                                                                                                                             Self-reported cognitive            Self-reported 
                                                                                                                              functioning complaint          questionnaire for 
                                                                                                                                                                       cognitive functions (46)
Lee                  2398 (21     Surgery                                                                                                                                                           ET is associated 
2016,           studies, 10≤24    only                                                                                                                                                                with impaired 
review               months           BC                                                                                                                                                                     cognitive
                          11>24            and                                                                                                                                                                  functioning
                         months)       healthy                 
Bakoyiannis       2381         No ET                                                                                                                                                         Verbal memory↓ in 
2016,                   ET +            BC/                                                                                                                                                                   4/5 studies
meta-              375 control,   healthy                                                                                                                                                           verbal fluency↓ i
analysis         longitudinal                                                                                                                                                                               n 2/6 studies
                     3-24 months                                                                                                                                                                         attention, working 
                                                                                                                                                                                                                        memory↓ in 
                                                                                                                                                                                                                        3/11 studies
                                                                                                                                                                                                                     working speed↓
                                                                                                                                                                                                                       in 1/6 studies
Underwood    911 ET +      No ET         (previous           Verbal learning/                                                                                              ET pts perform
2018,                249 BC   BC/healthy       chemo:                 memory ↓                                                                                                  worse in verbal
meta-                  + 662                                 some               visual learning/                                                                                             learning/memory;
analysis             healthy,                                 pts)                execution/speed                                                                                           all functions favor
                   cross-sectional/                   ET vs. no ET           psychomotor                                                                                                    tamoxifen
                      longitudinal                       AI vs. Tam               efficiency
                    (5-28 months)                   NSAI vs. SAI           visuospatial 
                                                                                                    function
AI: Aromatase inhibitor; BC: breast cancer; co: control, chemo: chemotherapy;  ET: endocrine therapy; NSAI: non-steroid AI; OFS: ovarian function
suppression; pts: patients; RT: radiotherapy; SAI: steroid AI; Tam: tamoxifen; yrs: year. 
tests suitable for serial repetition in a longitudinal study (52).
Indeed, we have realized that our methods were not optimal
for examining the specific domains of cognitive functioning
separately. Another problem is that lengthy testing may be
straining to many patients. Actually, in our study, only two of
the lost to follow-up patients confessed that neuropsycho-
logical tests were too burdensome for them. 
Several approaches exist to improve objective evaluation
of neuropsychological functioning. The use of circulating or
imaging biomarkers could serve to prevent and personalize
disease management (53). Correlations have been shown
between cognitive functioning and circulating factors such
as genetic and inflammatory markers, cerebral spinal fluid
constituents, and genetic polymorphisms including ApoE and
COMT-Val before and during the treatment of cancer
patients (17, 24, 53, 54). In the Mind Body Study, telomerase
activity, telomere length, DNA damage comet assay, soluble
TNF receptor-II were investigated (54). Higher DNA damage
score was related to lower executive function and memory
scores; decline in telomerase activity was associated with
lower attention, executive function and standardized motor
speed. The inflammation marker soluble TNF receptor-II was
elevated and related to cognitive difficulties early after
chemotherapy, but this association was absent 3-6 years after
the therapy (54). 
Another approach is the use of novel functional studies
such as the quantitative EEG (qEEG) and fMRI study for the
objective evaluation of cognitive functioning (55, 56). fMRI
study was performed on BC patients receiving chemotherapy,
BC patients without such treatment and healthy controls,
employing two task paradigms to evaluate therapy-related
differences. Task performance did not differ between groups,
and did not change over time. Nevertheless, the breast cancer
patients who received systemic treatment, showed increased
parietal activation compared to baseline indicating increasing
executive functioning task load as compared to the two types
of controls. This hyperactivation was associated with worse
physical functioning, fatigue and more cognitive complaints,
but recovery appeared over time (56). Within the Mind Body
Study, BC patients were examined by both neuropsychological
testing and qEEG. qEEG measures were associated with
neuropsychological performance and mood (55). 
In conclusion, our study indicates no cognitive impairment
during two years of ET. An important finding has been that
baseline cognitive scores and QOL dimensions are good
predictors of later anxiety and depression. Our results stress the
need of refined knowledge about the differential effects of ET
on cognition, anxiety, depression and QOL characteristics. 
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